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OBJECTIVE—Inﬂammatory mediators associated with type 1
diabetes are dilute and difﬁcult to measure in the periphery,
necessitating development of more sensitive and informative
biomarkers for studying diabetogenic mechanisms, assessing
preonset risk, and monitoring therapeutic interventions.
RESEARCH DESIGN AND METHODS—We previously uti-
lized a novel bioassay in which human type 1 diabetes sera were
used to induce a disease-speciﬁc transcriptional signature in
unrelated, healthy peripheral blood mononuclear cells (PBMCs).
Here, we apply this strategy to investigate the inﬂammatory state
associated with type 1 diabetes in biobreeding (BB) rats.
RESULTS—Consistent with their common susceptibility, sera
of both spontaneously diabetic BB DRlyp/lyp and diabetes
inducible BB DR/ rats induced transcription of cytokines,
immune receptors, and signaling molecules in PBMCs of healthy
donor rats compared with control sera. Like the human type 1
diabetes signature, the DRlyp/lyp signature, which is associated
with progression to diabetes, was differentiated from that of the
DR/ by induction of many interleukin (IL)-1–regulated genes.
Supplementing cultures with an IL-1 receptor antagonist (IL-1Ra)
modulated the DRlyp/lyp signature (P  10
6), while adminis-
tration of IL-1Ra to DRlyp/lyp rats delayed onset (P  0.007), and
sera of treated animals did not induce the characteristic signa-
ture. Consistent with the presence of immunoregulatory cells in
DR/ rats was induction of a signature possessing negative
regulators of transcription and inﬂammation.
CONCLUSIONS—Paralleling our human studies, serum signa-
tures in BB rats reﬂect processes associated with progression to
type 1 diabetes. Furthermore, these studies support the potential
utility of this approach to detect changes in the inﬂammatory
state during therapeutic intervention. Diabetes 59:2375–2385,
2010
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ype 1 diabetes is characterized by immune inﬁl-
tration of the pancreatic islets (insulitis) and
destruction of the insulin-producing -cells. It is
modeled by the biobreeding (BB) rat, in which
disease is associated with insulitis, hyperglycemia, and
exogenous insulin dependency (1,2). Like humans and the
nonobese diabetic (NOD) mouse, the major histocompat-
ibility complex (MHC) (insulin-dependent diabetes locus 1
[Iddm1]) contributes the largest genetic risk for type 1
diabetes in BB rats (3,4).
The DRlyp/lyp and DR/ congenic BB rat lines differ
only by the Iddm2 locus on chromosome 4 (5). Iddm2 has
been cloned, and the lymphopenia in DRlyp/lyp rats arises
from a mutation in the Gimap5 gene, which encodes a
mitochondrial protein necessary for postthymic T-cell
survival (6,7). The spontaneously diabetic phenotype,
which occurs in 100% of DRlyp/lyp rats during adoles-
cence (65.3  6.3 days), is elicited through deﬁciency in
regulatory T-cells (TREG cells), as diabetes can be rescued
through adoptive transfer of this population (8).
Type 1 diabetes in the nonlymphopenic BB DR/ rat,
which possesses a wild-type Gimap5, is inducible through
depletion of TREG cells (9,10). Thus, in all BB rats, there is
predisposition for type 1 diabetes that is manifest upon
loss of immune regulation. This predisposition is absent in
Wistar-Furth (WF) rats, which share the RT1
u MHC hap-
lotype, since depletion of TREG cells does not induce
disease. This susceptibility is also absent in Fischer rats,
as introgression of RT1
u/u and/or Gimap5
/ is insufﬁcient
for type 1 diabetes development (11).
In addition to T-cell responses, cytokines are important
in diabetogenesis (12), as they are associated with -cell
destruction and disease status in both humans and spon-
taneous rodent models. Previously, we applied a sensitive
genomics-based bioassay to investigate the presence of
proinﬂammatory factors in human type 1 diabetes. The
approach used sera of patients with recent-onset type 1
diabetes or healthy control subjects to induce transcrip-
tion in unrelated healthy peripheral blood mononuclear
cells (PBMCs) (13). Recent-onset type 1 diabetes sera
induced a transcriptional proﬁle that included genes re-
lated to innate immunity and genes regulated by interleu-
kin (IL)-1. The signature was distinct from that induced by
sera of healthy control subjects or long-standing type 1
diabetic patients, and analysis of a limited number of
preonset samples showed that it preceded disease and the
development of autoantibodies. Our ﬁndings in type 1
diabetes, and those reported for systemic-onset juvenile
idiopathic arthritis (14), support that expression signa-
tures induced by serum factors associated with different
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active disease, and are mechanistically informative.
Here, we examine the serum-induced transcriptional
signatures of DRlyp/lyp and DR/ rats in an attempt to
bridge the divide between invasive studies allowed in
animal models and the peripheral blood sampling possible
in humans. These studies identify an innate immune
signature associated with progression to type 1 diabetes in
DRlyp/lyp rats that is modulated by the addition of an IL-1
receptor antagonist (IL-1Ra) in vitro and ﬁnd that admin-
istration of IL-1Ra to pre-diabetic animals modulates the
inﬂammatory signature and delays disease onset.
RESEARCH DESIGN AND METHODS
Brown Norway (BN) and BB rats were propagated as described (5,6). Before
euthanization, animals were fasted for 16 h, and those possessing blood
glucose levels 130 mg/dl were disqualiﬁed from studies of pre-diabetes. Rats
were anesthetized under isoﬂuorane, and blood was collected by heart
puncture. Serum was separated by centrifugation then stored at 80°C until
use.
Human recombinant IL-1Ra (hIL-1Ra) (350 g/kg/day) or vehicle (saline)
was delivered to DRlyp/lyp rats by intraperitoneal injection. Dosage was
based upon previous hIL-1Ra administration to rodents (15,16). Treatment
was initiated by day 30 and continued either through day 40 or through
diabetes onset. Diabetes onset was deﬁned as the ﬁrst of two consecutive
blood glucose measurements 250 mg/dl. Survival was analyzed with the
Kaplan-Meier method. All procedures were approved by the Medical College
of Wisconsin Institutional Animal Care and Use Committee.
PBMC cultures. Fresh PBMCs of healthy BN rats (	180-day-old males, to
avoid variation introduced by estrous or pubertal status) were isolated by
density gradient centrifugation. As described (13), transcription was induced
by culturing PBMCs for6ha t37°C in 5% CO2 with 20% autologous BN
(self-baseline control), allogeneic BN (healthy unrelated control), DRlyp/lyp,
or DR/ serum. Indicated cultures were supplemented with 1 ng/ml rat
IL-1 or 1 g/ml rat IL-1Ra. RNA was extracted using TRIzol reagent,
ampliﬁed/labeled using the express kit (Affymetrix, Santa Clara, CA), and
hybridized to the Affymetrix Rat Genome 230 2.0 Array. RNA from each
culture was independently analyzed. Image data were quantiﬁed with Af-
fymetrix Expression Console Software and normalized with Robust Multichip
Analysis (www.bioconductor.org/) to determine signal log ratios. ANOVA was
conducted and false discovery rates (FDRs) were determined using Partek
Genomics Suite version 6.2. To capture the most reliable data, limit the length
of gene lists, and facilitate focused pathway analyses, differentially expressed
probe sets were deﬁned as those possessing an FDR 10% and log2 ratio
0.5 between the compared groups. Ontological analysis was performed with
the Database for Annotation, Visualization, and Integrated Discovery (DAVID)
(17). Hierarchical clustering was conducted with Genesis (18). Orthologous
rat and human probe sets were mapped using the Affymetrix support
document (HG-U133_Plus_2.na29.orthologue.csv.zip). All raw data ﬁles have
been deposited in The National Center for Biotechnology Information Gene
Expression Omnibus (accession no. GSE19537).
Direct detection of inﬂammatory mediators. Sera of day 60 BB rats and
day 180 BN rats were assayed with the BeadLyte cytokine assay kit (Millipore,
Billerica, MA), per the manufacturer’s protocol, and a Bio-Plex Luminex 100
XYP instrument. Concentrations were calculated with the Bio-Plex Manager
4.1 software and a ﬁve-parameter curve-ﬁtting algorithm applied for standard
curve calculations. IL-33 levels in sera and IL-1/-
 levels in conditioned
culture medium were measured with Quantikine enzyme-linked immunosor-
bent assays (ELISAs) (R&D Systems, Minneapolis, MN), and gram-negative
bacterial endotoxins (lipopolysaccarides [LPS]) were measured by the Limu-
lus amoebocyte lysate assay (Associates of Cape Cod, Falmouth, MA).
Western blot analysis for anti–hIL-1Ra antibodies. hIL-1Ra (17 kDa) was
electrophoresed through polyacrylamide gels (10–20% Tris-HCl) and trans-
ferred to polyvinylidene diﬂuoride membranes. Membranes were blocked for
1 h with 5% BSA and 0.1% Tween-20 at room temperature then probed with a
1:2,000 dilution of sera from hIL-1Ra or saline-treated DRlyp/lyp rats overnight
at 4
 C. Blots were washed three times with 1  TBS with 0.1% Tween 20 then
incubated with a 1:2,000 dilution of anti-rat IgG, horseradish peroxidase–
linked antibody in blocking solution for1ha troom temperature. After three
washes, the Enhanced Chemiluminescence (ECL) Plus System (Amersham,
Piscataway, NJ) was used for visualization.
RESULTS
Induction of transcriptional signatures. To determine
whether inﬂammatory mediators related to diabetogenesis
could be detected through their ability to induce transcrip-
tion, PBMCs of healthy, day 180 BN rats were cultured
with day 60 DRlyp/lyp (representing the period immedi-
ately before onset), day 60 DR/, allogeneic BN, or
autologous BN serum. To ensure induced transcription
was not related to elevated blood glucose levels, only sera
of normoglycemic, preonset rats were used. In preliminary
studies, we observed that day 60 DRlyp/lyp serum, like
human recent-onset sera, induced many genes regulated
by IL-1. Therefore, PBMCs were also cultured with day 60
DRlyp/lyp serum supplemented with IL-1Ra as well as
autologous BN serum supplemented with IL-1, to respec-
tively block or induce IL-1–mediated gene expression.
Culture of BN PBMCs with DRlyp/lyp or DR/ sera
regulated, within the threshold values, 1,979 and 2,904
probe sets, respectively, relative to culture with allogeneic
BN sera.
Analysis of genes commonly regulated by day 60
DR/ and DRlyp/lyp sera. As reﬂected in the Venn
diagram illustrated in Fig. 1A, culture of BN PBMCs with
either DRlyp/lyp or DR/ sera regulated a total of 3,971
probe sets (supplement A Fig. 1A, available at http://
diabetes.diabetesjournals.org/cgi/content/full/db10-0372/DC1).
Consistent with type 1 diabetes susceptibility in both
strains, the signatures share a signiﬁcantly nonrandom
(P  10
6, 

2 test), commonly regulated intersection of
912 probe sets that represents 46.1 and 31.4% of the probe
sets induced by either DRlyp/lyp or DR/ serum, respec-
tively. Hierarchical clustering (Fig. 1B) shows the related-
ness of the ﬁve experimental conditions for this subset.
These 912 shared probe sets were annotated with DAVID,
which identiﬁed signiﬁcantly regulated gene ontology bio-
logical processes related to immunological activation,
antigen presentation, and intracellular signaling, in partic-
ular through the nuclear factor (NF) B pathway (Table 1
and supplement B).
NFB is a transcriptional regulator of innate and adap-
tive immunity (19) that is activated through events such as
binding of IL-1 to IL-1R1 or LPS to toll-like receptor (TLR)
4. These events converge at a set of I-B kinases that
phosphorylate the inhibitory I-B proteins (NFKBIA and
NFKBIB) leading to their degradation, allowing release
and nuclear translocation of cytoplasmic NFB, where it
facilitates target gene transcription. Both DRlyp/lyp and
DR/ sera induced Nfkb2, which encodes the p100
precursor that is cleaved to produce the NFB p52 protein;
the receptor-interacting serine-threonine kinase 2 (Ripk2),
a potent activator of NFB; as well as tumor necrosis
factor (TNF) receptor superfamily member 25 (Tnfrsf25),
which stimulates NFB activity (20). Sera of either BB rat
induced transcription of genes related to intracellular
signaling, including signal transducer and activator of
transcription 2 (Stat2) and mitogen-activated protein ki-
nase activated protein kinase 5 (Mapkapk5), which is
activated by MAPKs in response to exposure to proinﬂam-
matory cytokines. DRlyp/lyp and DR/ sera also in-
duced transcription of genes encoding chemokines (Ccl2,
Cxcl16) and receptors including Tlr4, Tlr7, Ccr1, and
Cd14, which are important in TLR4 signaling. Other genes
related to immune function included IL-1R–associated
kinase 3 (Irak3) and intercellular adhesion molecule 1
(Icam1). Both DRlyp/lyp and DR/ sera induced the
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n=3971
intersection 
n=912
unique to DR lyp/lyp  
n=1067
unique to DR+/+  
n=1992
DRlyp/lyp:
BN allogeneic
n=1979
DR+/+:
DRlyp/lyp
DRlyp/lyp + IL-1Ra
BN + IL-1B
BN Allogeneic
DR+/+
BN allogeneic
n=2904
A B
C
n=912
DRlyp/lyp
DRlyp/lyp + IL-1Ra
BN + IL-1B
BN Allogeneic
DR+/+
Expression Ratio
Relative to Autologous
Entrez
ID Gene DR+/+
DRlyp/lyp
DRlyp/lyp + IL-1Ra
Ccl2 24770 4.59 5.45 4.04
Cd14 60350 3.33 3.25 3.62
Ccr1* 57301 2.68 2.53 2.17
Hmox1 24451 2.49 2.19 2.18
Thbd* 83580 2.26 2.22 2.18
Ctsl1 25697 2.04 1.83 1.56
Nek6 360161 1.60 1.70 1.53
Tlr4* 29260 1.43 1.40 1.20
Klf4 114505 1.88 3.44 2.03
Bcl3 680611 1.47 2.52 1.86
Klf2 306330 1.28 2.55 1.83
Plaur* 117540 1.67 1.36 1.57
Plscr1* 29427 1.64 1.58 1.31
Aif1 50692 1.56 1.91 1.11
RT1-Bb 500592 1.52 1.93 1.69
Ripk2* 309622 1.47 1.64 1.28
Tnfrsf25 362491 1.46 1.59 1.49
Stat2 288774 1.28 1.50 1.27
Tlr7* 317468 1.33 1.33 1.14
Mapkapk5 498183 1.46 1.33 1.33
Map4k1 292763 1.22 1.68 1.52
Map4k2 293694 1.21 1.94 1.33
Mx1 24575 1.30 1.26 1.25
Birc3 78971 1.29 1.21 1.09
Irak3 314870 1.23 1.27 1.17
Lta4h 299732 1.41 1.16 1.32
Icam1* 25464 1.33 1.31 1.54
Eif1a 317163 1.30 1.40 -1.03
Rhoh 305341 1.22 1.28 1.16
Psme1 29630 1.27 1.11 1.13
Tnfrsf1b 156767 1.20 1.05 1.20
Faim 140930 1.23 1.13 1.02
Ctse 25424 1.19 1.07 1.02
Iﬁ30* 290644 1.18 1.07 1.06
Hsf1 79245 1.29 1.29 1.51
Card11 1.15 1.29 1.43
Cd8a 24930 1.15 1.18 1.04
Nfkb2 309452 1.04 1.02 1.33
Lat 81511 1.09 -1.10 -1.01
Gpsm3* 406163 -1.07 1.14 1.11
304314
 -4
 +4
fold of change
relative to 
autologous
FIG. 1. Analysis of genes commonly regulated by day 60 DR/ and DRlyp/lyp sera relative to allogeneic BN sera. PBMCs of four BN rats each
were cultured under six different conditions: 1) autologous serum (n  4 cultures), 2) autologous serum spiked with IL-1 (1 ng/ml, n  4
cultures), 3) allogeneic BN serum (n  15 cultures), 4)aD R lyp/lyp serum pool (n  4 cultures), 5)aD R lyp/lyp serum pool supplemented with
IL-1Ra (1 g/ml, n  4 cultures), and 6)D R / serum pool (n  4 cultures). The serum pools were created from an equal contribution of six
individual male rats. Gene expression was measured independently in each culture, and all data were normalized with that of the autologous
induction to account for gene expression induced by placing the PBMCs into culture. A: A Venn diagram illustrating the relationship between the
gene expression induced in the DRlyp/lyp vs. BN allogeneic and DR/ vs. BN allogeneic inductions (log2 ratio > 0.5-  1.4-fold; ANOVA FDR
<0.10). B: The mean expression of the ﬁve experimental conditions were examined for relatedness by hierarchical clustering using the commonly
regulated probe sets (n  912) of the DRlyp/lyp vs. BN allogeneic and DR/ vs. BN allogeneic intersection. Note the similarity between the
DRlyp/lyp and DR/ signatures and the failure of IL-1Ra to highly inﬂuence the DRlyp/lyp signature for this subset of genes. C: Well-annotated
genes regulated in BN PBMCs when cultured with either DRlyp/lyp or DR/ sera related to immune activation. *Orthologues regulated by
human type 1 diabetes sera (13). The scale represents the fold of change between the serum tested relative to autologous serum (fourfold to
fourfold).
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matory inhibitor that functions through the binding of
coactivators necessary for optimal NFB activity (21), and
B-cell CLL/lymphoma three (BclIII), an IL-10–inducible
gene that impairs binding of NFB complexes to DNA
(19,22). Importantly, all 912 probe sets of the intersection
exhibited directionally concordant inductions by either
DRlyp/lyp or DR/ sera relative to allogeneic BN sera.
Furthermore, when directly comparing expression levels
between the DRlyp/lyp and DR/, only two probes sets
(2 of 912, 0.2%) were differentially expressed (Klf4 and
Map4k2, supplement A). Overall, analysis of the intersec-
tion revealed that culturing BN PBMCs with either DR/
or DRlyp/lyp sera, compared with allogeneic BN sera,
induced transcription consistent with immunological acti-
vation (Fig. 1C).
Independent analysis of genes regulated by DRlyp/
lyp and DR/ sera. To reveal processes associated
with progression to type 1 diabetes, the DRlyp/lyp and
DR/ serum signatures were independently analyzed.
The mean expression from each of the ﬁve experimental
conditions was subjected to hierarchical clustering using
the 1,979 or 2,904 probe sets respectively regulated by
DRlyp/lyp sera or DR/ sera relative to the BN alloge-
neic induction (Figs. 2A and C). Ontological analysis of
the DRlyp/lyp signature identiﬁed biological processes
related to proinﬂammatory processes possessing higher
numbers of associated genes with greater signiﬁcance
compared with the analyses of the DRlyp/lyp:DR/
intersection or the DR/ signature (Table 1 and
supplement B). Speciﬁcally, DRlyp/lyp sera regulated
biological processes related to antigen presentation,
inﬂammation, and leukocyte migration. Annotated
genes related to these functions included induction of
Il1b, Tlr2, Il18, Icam2, proteasome subunit  type 1,
(Psmb1), Stat1, and numerous MHC class II genes.
Among the 1,979 probe sets regulated by DRlyp/lyp sera
were central components of the NFB cascade, includ-
TABLE 1
Signiﬁcantly regulated gene ontology biological processes
Biological process* Count Percentage P value
Day 60 DRlyp/lyp:DR/ intersection (n  912 probe sets)
Antigen processing and presentation of exogenous antigen 7 0.76 2.55  10
4
Immune system process 49 5.31 2.28  10
3
Antigen processing and presentation 10 1.08 4.57  10
3
Antigen processing and presentation of peptide antigen 8 0.87 8.62  10
3
Immune response 33 3.58 1.21  10
2
Regulation of transcription 87 9.44 1.89  10
2
Regulation of signal transduction 33 3.58 2.68  10
2
Regulation of transcription, DNA dependent 79 8.57 2.71  10
2
Regulation of gene expression 91 9.87 3.54  10
2
Myeloid leukocyte mediated immunity 4 0.43 3.65  10
2
I-B kinase/NFB cascade 11 1.19 6.94  10
2
Day 60 DRlyp/lyp (n  1,979 probe sets)
Antigen processing and presentation of exogenous antigen 14 0.71 6.54  10
9
Antigen processing and presentation 22 1.11 4.47  10
6
Antigen processing and presentation of peptide antigen 17 0.86 3.55  10
5
Immune system process 95 4.80 3.50  10
3
I-B kinase/NFB cascade 24 1.21 6.23  10
3
Immune response 65 3.28 1.00  10
2
Myeloid leukocyte mediated immunity 6 0.30 2.15  10
2
Leukocyte migration 9 0.45 8.73  10
2
Day 60 DR/ (n  2,904 probe sets)
Regulation of transcription 260 9.33 8.75  10
8
Regulation of gene expression 276 9.90 2.13  10
7
Regulation of transcription, DNA dependent 237 8.50 3.84  10
7
Regulation of signal transduction 91 3.27 1.83  10
4
Regulation of transcription from RNA polymerase II promoter 81 2.91 2.64  10
3
Negative regulation of transcription, DNA dependent 38 1.36 9.95  10
3
Antigen processing and presentation of exogenous antigen 8 0.29 1.21  10
2
Negative regulation of transcription 49 1.76 1.34  10
2
Antigen processing and presentation 17 0.61 1.40  10
2
Negative regulation of gene expression, epigenetic 5 0.18 2.17  10
2
I-B kinase/NFB cascade 25 0.90 3.33  10
2
Immune system process 105 3.77 3.75  10
2
Day 40 PBS-treated DRlyp/lyp (n  1,526 probe sets)
Antigen processing and presentation 27 1.73 2.63  10
11
Antigen processing and presentation of peptide antigen 21 1.35 1.89  10
9
Immune system process 96 6.17 1.96  10
6
Immune response 67 4.30 2.31  10
5
Antigen processing and presentation of exogenous antigen 9 0.58 1.92  10
4
I-B kinase/NFB cascade 25 1.61 1.98  10
4
*Genes identiﬁed in Figs. 1, 2, and 4 were analyzed for signiﬁcantly regulated annotations by DAVID. If an annotation was identiﬁed in more
than one of the analyses, it is listed accordingly. Complete lists of annotations are provided in supplement B. The P value deﬁnes the
signiﬁcance of the association of a particular biological process with the gene list analyzed.
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NFB activity, including casein kinase 2  subunit
(Csnk2b), a potent NFB activator that directly phosphory-
lates NFKBIA (23), baculoviral IAP repeat-containing 2
(Birc2) (20), and Cd40 (Fig. 3A and supplement A).
When examining the 1,067 probe sets uniquely regulated
by DRlyp/lyp sera (i.e., those excluding the intersection)
(Fig. 2B), a role for IL-1 in induction of the signature
became evident, as blocking IL-1R1 by adding IL-1Ra to
cultures modulated the signature, yielding one more sim-
ilar to that induced by DR/ sera. Speciﬁcally, after
adding IL-1Ra to the culture, expression of 83.3% (889 of
1,067) of the DRlyp/lyp-speciﬁc probe sets no longer met
the threshold values (P  10
6, 

2 test). Among 912 genes
of the intersection, only 40% (374) were inﬂuenced by the
addition of IL-1Ra (P  10
6, 

2 test). When examining
1,992 probe sets uniquely regulated by DR/ sera (Fig.
2D), addition of IL-1Ra to the DRlyp/lyp culture resulted in
induction of a signature more similar to that of the DR/
culture in terms of fold of change. However, the overall
expression levels were less inﬂuenced, in that among 1,992
genes regulated in the DR/ culture, only 26.2% (521 of
A
C
 -4  +4
fold of change relative to autologous
D
B
n=1,979 n=1,067
n=2,904 n=1,992
intersection
DRlyp/lyp 
DR+/+ 
DRlyp/lyp
DRlyp/lyp + IL-1Ra
BN + IL-1B
BN Allogeneic
DR+/+
DRlyp/lyp
DRlyp/lyp + IL-1Ra
BN + IL-1B
BN Allogeneic
DR+/+
DR
DRlyp/lyp + IL-1Ra
BN + IL-1B
BN Allogeneic
DR+/+
DRlyp/lyp
DRlyp/lyp + IL-1Ra
BN + IL-1B
BN Allogeneic
DR+/+
lyp/lyp
FIG. 2. Independent analysis of genes regulated by DRlyp/lyp and DR/ sera. In all cases, replicates were averaged and the relatedness of the
ﬁve conditions was analyzed by hierarchical clustering. A: Illustrates all probe sets regulated between the DRlyp/lyp vs. BN allogeneic inductions
including probe sets of the DRlyp/lyp:DR/ intersection (n  1,979). B: Illustrates all probe sets regulated between the DRlyp/lyp vs. BN
allogeneic inductions excluding probe sets of the DRlyp/lyp:DR/ intersection (n  1,067). Note the distinctiveness of the DRlyp/lyp signature
relative to the DR/ and the inﬂuence of IL-1Ra in impairing induction of the DRlyp/lyp signature in panels A and B. C: Illustrates all probe sets
regulated between the DR/ vs. BN allogeneic inductions including probe sets of the DRlyp/lyp:DR/ intersection (n  2,904). D: Illustrates
all probe sets regulated between the DR/ vs. BN allogeneic inductions excluding probe sets of the DRlyp/lyp:DR/ intersection (n  1,992).
Note the similarity between DRlyp/lyp and DR/ signatures and how the addition of IL-1Ra to DRlyp/lyp cultures enhances expression in C and
D. The scale represents fold of change between the serum tested relative to autologous serum (fourfold to fourfold).
M. KALDUNSKI AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, OCTOBER 2010 23791,992) of the probe sets in the DRlyp/lyp  IL-1Ra culture
were regulated to meet the threshold values. These statis-
tical ﬁndings are reﬂected in Figs. 2B and D and show gene
expression arising through IL-1R1 signaling accounts for a
large part of the difference between the DRlyp/lyp and
DR/ signatures. Furthermore, addition of IL-1Ra to
DRlyp/lyp cultures reduced gene expression annotated as
proinﬂammatory (Fig. 2B) and enhanced gene expression
annotated as being regulatory (Fig. 2D). Addition of IL-1
to PBMCs cultured with autologous BN sera induced a
modest signature, more similar to that induced by that of
BB rat sera than cultures possessing BN allogeneic sera (Fig.
2), regulating 209 of 3,971 probe sets regulated by DR/ or
DRlyp/lyp serum relative to BN allogeneic serum.
A
B
Il1b* 24494 1.61 1.51 1.81
Cr2* 289395 1.52 -1.01 1.07
Ccl3 25542 1.49 1.18 1.35
Azi2 316051 1.42 1.23 1.03
Tnip2 305451 1.31 1.17 1.06
Il18 29197 1.30 1.16 1.19
Mx2* 286918 1.32 1.11 1.12
Hla-dmb 294273 1.30 1.12 1.25
Hla-dma 294274 1.47 1.12 1.26
RT1-Db1* 294270 1.44 1.00 1.14
Mt1a* 24567 1.23 1.13 1.02
Stat1* 25124 1.24 1.10 1.10
Btk 367901 1.20 1.13 1.07
Mapk1 116590 1.16 1.08 1.02
Nfkbib 81525 1.11 1.08 1.04
Prkd3* 313834 1.35 -1.09 -1.02
Psmb9 24967 1.33 -1.05 1.01
Rab20* 689377 1.29 -1.01 1.09
Tlr2* 310553 1.15 -1.06 1.07
Fcrla* 304965 1.19 1.01 1.09
Rnf167 360554 1.14 -1.06 1.12
Csnk2b 81650 1.25 -1.39 1.08
Icam2 360647 1.16 -1.20 1.17
Birc2 60371 1.32 -1.11 1.02
Cd74 25599 1.14 -1.03 1.17
Cd40 171369 1.27 -1.02 1.08
Nup85 287830 1.25 1.02 1.06
Nfkbia 25493 1.27 -1.15 -1.03
Eef1d 300033 1.20 -1.21 1.02
Psmb8 24968 1.24 -1.13 1.05
Faf1 140657 1.12 -1.15 1.02
Ccdc101 293488 1.14 -1.44 -1.05
Gzmm 29252 1.09 -1.27 1.01
Bet1l 54400 1.28 -1.34 -1.16
Txnl4b* 292008 1.29 -1.24 -1.01
Eif2s3x* 299027 1.15 -1.25 -1.07
Stk19 361800 1.02 -1.55 -1.11
Cklf 245978 1.16 1.00 -1.23
Itga6* 114517 -1.43 -1.26 -1.21
Nlk* 497961 -1.92 -1.46 -1.19
Egr1 24330 1.76 2.66 2.26
Cpsf6 299811 1.63 2.93 1.72
Elk3 362871 1.26 2.51 1.52
Tcf7 363595 1.20 2.47 1.69
Smad7 81516 1.27 2.17 2.07
Map3k7ip2 308267 1.38 2.26 1.72
LOC684513 684513 1.50 2.42 1.84
Mll5 311968 1.37 2.37 1.92
Mll5 311968 1.37 1.72 1.91
Irak2 362418 1.39 1.50 1.59
Pou2f1 171068 1.13 1.64 1.72
Irf2 290794 1.15 2.09 1.35
RGD1565584 293112 1.12 1.77 1.28
Zeb1 25705 1.26 1.71 1.54
Maml1 303101 1.16 1.67 1.47
Ncor1 54299 1.16 1.91 1.49
Runx1 50662 1.14 1.98 1.50
Cbx7 362962 1.14 1.90 1.49
Ep300 170915 1.09 1.80 1.36
Smarca4 171379 -1.02 1.95 1.61
Mdm4* 304798 1.38 1.67 1.21
Iﬁt2* 294091 1.38 1.91 1.39
Ctcf 83726 1.36 1.97 1.62
Gtf2ird1 246770 1.34 1.97 1.43
RGD1565584 293112 1.26 1.86 1.30
Zbtb7a 117107 1.17 1.98 1.38
Jun* 24516 1.14 1.80 1.35
Pias2 83422 1.14 1.65 1.39
Sirt4 304539 1.14 1.63 1.44
Rybp 312603 1.12 1.73 1.43
Mll1 315606 -1.01 1.85 1.41
Ncor1 54299 1.11 1.44 1.24
Mbd2 680172 1.04 1.49 1.12
Foxp1 297480 1.13 1.48 1.47
Usp7 360471 1.07 1.48 1.37
Pura 307498 1.00 1.44 1.32
Nek7 360850 1.02 1.23 1.03
Ncor1 54299 -1.06 1.48 1.13
Grk6 59076 -1.13 1.32 1.11
Nfkbie 316241 1.15 1.94 1.42
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FIG. 3. Well-annotated regulated probe sets were uniquely identiﬁed in the DRlyp/lyp vs. BN allogeneic induction (A) or the DR/ vs. BN
allogeneic induction (B). *Orthologues regulated by human type 1 diabetes sera (13). The scale represents the fold of change between the serum
tested relative to autologous serum (fourfold to fourfold).
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regulated by DR/ sera revealed the greatest number of
highly signiﬁcant biological processes, and these annota-
tions were primarily related to regulation of gene expres-
sion (Table 1 and supplement B). Numerous genes related
to negative regulation of inﬂammation and NFB signaling
were regulated by DR/ sera, including Nfkbie,a n
inhibitor of NFB (24); the transcriptional repressors zinc
ﬁnger E-box binding homeobox 1 (Zeb1); zinc ﬁnger and
BTB domain containing 7a (Zbtb7a); interferon regulatory
factor 2 (Irf2); ETS domain-containing protein Elk-3; the
inhibitor of activated STAT 2 (Pias2); suppressor of
cytokine signaling-5 (Socs5); the cell cycle inhibitor; my-
eloid/lymphoid or mixed-lineage leukemia 5 (Mll5); and
others (Fig. 3B).
While the sera of either BB substrain induced gene
expression consistent with immune activation, DRlyp/lyp
sera induced an inﬂammatory signature consistent with
the presence of IL-1, whereas that of the DR/ sera can
be characterized as largely immunoregulatory. Among the
genes regulated by DRlyp/lyp and DR/ sera were 87
orthologues previously identiﬁed among 587 genes regu-
lated by human type 1 diabetes sera (Figs. 1 and 3 and
supplement A) (13).
Direct detection of inﬂammatory mediators. In an
effort to account for the induced signatures, cytokine
levels were measured by ELISA in the DRlyp/lyp,D R /,
and BN sera used in the expression studies (Table 2).
Measurable differences in IL-1
 or IL-1 levels between
DRlyp/lyp,D R /, or BN rat sera were not detected,
raising the question whether the induced transcription
measured after6ho fculture was a primary effect of IL-1
TABLE 3
IL-1 levels in conditioned medium after PBMC culture with DRlyp/lyp,D R /, and BN sera
Duration
Day 60
DRlyp/lyp
Day 60
DRlyp/lypIL-1Ra
Day 60
DR/
Day 180
BN allogeneic
Day 180
BN autologous
0 h 2.9  1.7 1.7  1.2 4.4  2.0 2.2  1.3 2.0  2.0
1 h 5.3  2.3 5.3  2.0 4.4  1.8 0.0  0.0 0.7  0.8
3 h 4.7  2.2 7.7  6.7 4.1  2.3 3.3  2.9 0.8  0.5
6 h 3.6  1.4 5.2  1.9 7.7  3.5 2.7  2.5 1.9  0.9
12 h 7.0  2.5 10.3  3.8 4.6  1.7 9.0  4.0 6.6  3.3
24 h 12.4  3.3*† 10.1  5.4 9.5  4.1 1.2  0.7 4.0  1.8
Data are means  SE of four cultures per group (pg/ml). Each culture was tested in duplicate using the IL-1 Quantikine ELISA kit (R&D
Systems). In cultures possessing autologous BN sera supplemented with 1 ng/ml IL-1, on average 816.3  51.7 pg/ml was detected across
the six time points. Assay sensitivity: 5 pg/ml. *P  0.05 Student t test vs. 0 h time point. †P  0.05 Student t test vs. day 180 allogeneic
BN sera at 24 h of culture.
TABLE 2
Cytokine/chemokine levels in DRlyp/lyp,D R /, and BN rats
Cytokine Day 60 DRlyp/lyp Day 60 DR/ Day 180 BN
Lower detection
limit (pg/ml)
IL-1a 0.0  0.0 0.0  0.0 0.0  0.0 27
IL-1b 15.6  4.4 11.7  6.0 11.8  8.1 27
IL-2 20.6  6.9 23.8  9.7 3.9  3.9 75
IL-4 1.9  1.9 5.1  3.9 6.7  3.3 27
IL-5 19.6  10.8 0.0  0.0 0.0  0.0 10
IL-6 1.6  1.3 0.0  0.0 1.8  1.8 250
IL-9 224.1  43.9 105.0  28.5 102.9  55.8 250
IL-10 107.2  30.0 58.2  19.4 42.7  24.2 27
IL-13 90.4  21.1*† 14.1  2.2 14.1  4.4 27
IL-17 0.0  0.0 0.0  0.0 0.0  0.0 10
IL-18 14.6  3.0 12.4  3.3 3.2  1.6 10
Granulocyte colony-stimulating factor 0.0  0.0 0.0  0.0 0.0  0.0 10
Granulocyte/macrophage colony-stimulating factor 6.9  5.2 0.0  0.0 2.9  2.9 27
Growth-regulated oncogene alpha, chemokine CxCl1 302.5  45.0 227.1  29.9 199.8  34.7 27
Eotaxin 0.9  0.9 0.0  0.0 8.4  2.8 27
Interferon- 3.9  2.3 1.6  1.0 0.0  0.0 27
IP-10 0.0  0.0 0.0  0.0 0.2  0.2 10
Leptin 1,727.4  607.1 2,478.8  602.3 1,438.4  203.9 10
Monocyte chemoattractant protein (CCL2) 80.0  32.9 45.8  21.1 87.6  7.3 75
Macrophage inﬂammatory protein-1 alpha 0.0  0.0 0.0  0.0 0.0  0.0 10
Rantes 1,496.9  416.0 6,757.0  4,493.9 1,530.2  176.7 27
TNF-
 1.6  0.9 0.0  0.0 16.9  3.1 10
Vascular endothelial growth factor 0.0  0.0 0.0  0.0 0.0  0.0 27
IL-12p70 0.0  0.0 0.0  0.0 0.0  0.0 27
IL-33 8.9  0.4 6.8  0.1 5.6  0.5 7
LPS§ 1.30  0.2‡ 1.34  0.2‡ 0.87  0.1 0.5
Data are means  SE of six rats per group (pg/ml). Each sample was tested in duplicate using the Millipore BeadLyte cytokine assay kit, with
the exception of IL-33 and LPS. *P  0.01 Wilcoxon rank-sum test vs. BN; †P  0.01 Wilcoxon rank-sum test DRlyp/lyp vs. DR/;‡ P 
0.05 Wilcoxon rank-sum test vs. BN; §conversion from endotoxin units (EU) to picograms (pg) is based upon 1 EU  100 pg.
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FIG. 4. Treatment of DRlyp/lyp rats with hIL-1Ra. A: Longitudinal monitoring of DRlyp/lyp rats treated with 350 g/kg/day human recombinant
IL-1Ra (n  16, dashed line) or saline (n  23, solid line). Agents were delivered intraperitoneally in saline. Treatment was initiated by day 30
(prior to insulitis). Fasting blood glucose was measured three times per week, and type 1 diabetes onset was deﬁned as the ﬁrst of two
consecutive fasting blood glucose measurements >250 mg/dl. hIL-1Ra–treated rats survived 71  11 days (range 53–100), while saline-treated
controls survived 61  6 days (53–75) (P  0.007, log-rank test). B: Detection of anti–hIL-1Ra antibodies in IL-1Ra–treated DRlyp/lyp rats.
Indicated amounts of hIL-1Ra (17 kDa) were loaded onto polyacrylamide gels, electrophoresed, and blotted. Membranes were probed with a
1:2,000 dilution of onset sera from hIL-1Ra–treated (top left blots), saline-treated (top right blot), day 40 hIL-1Ra–treated (bottom left blot), or
saline-treated (bottom right blot)D R lyp/lyp rats. C: A Venn diagram illustrating the relationship between the gene expression induced between
the PBS-treated DRlyp/lyp vs. BN allogeneic and hIL-1Ra–treated DRlyp/lyp vs. BN allogeneic inductions (244 log2 ratio >0.5- 1.4-fold;
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the PBMCs in response to other dilute mediators in
DRlyp/lyp sera. Conditioned medium of cultures supple-
mented with the various sera were assayed for IL-1
 and
IL-1 at 0, 1, 3, 6, 12, and 24 h. While IL-1
 was not
detected at all, signiﬁcant detectable levels of IL-1 were
measured in only DRlyp/lyp cultures at 24 h but not at or
prior to 6 h (Table 3). This supports the hypothesis that the
6 h transcriptional response is primary and is due in part to
IL-1 itself, as lower IL-1 protein was not signiﬁcantly
detected in the DR/ and DRlyp/lyp  IL-1Ra cultures.
This parallels the signiﬁcant detection of Il1b transcript
only in cultures supplemented with DRlyp/lyp sera. Signif-
icant differences in serum IL-10 were not observed; how-
ever, consistent with the transcriptional signatures, levels
in DR/ and DRlyp/lyp serum were greater than that
measured in the BN rat. IL-13 was the only signiﬁcantly
upregulated cytokine detected in serum of the day 60
DRlyp/lyp rat.
Recent studies have identiﬁed increased levels of LPS in
human type 1 diabetic patients (25). Given that TLR4 and
IL-1R1 signaling both are mediated through the adaptor
protein MyD88 to activate NFB, we investigated LPS
serum levels. On average, signiﬁcantly higher LPS levels
were detected in the DRlyp/lyp and DR/ rat serum
compared with that of BN rats (Table 2), consistent with
the signiﬁcant induction of Il1b transcript in cultures
possessing with DRlyp/lyp sera even when supplemented
with IL-1Ra (supplement A).
Delay of BB rat type 1 diabetes through IL-1R block-
ade. Given the parallels between the signatures induced
by human type 1 diabetes and DRlyp/lyp sera, in terms of
overrepresentation of transcripts regulated by IL-1 and
modulation of the DRlyp/lyp signature upon addition of
IL-1Ra to cultures, we tested the effectiveness of IL-1Ra in
delaying type 1 diabetes onset in BB rats. The treatment of
BB rats with rat IL-1Ra is cost prohibitive, while hIL-1Ra
shares 70% amino acid homology with rat IL-1Ra and is
bioactive in rat (15,26). Thus, we reasoned that if IL-1–
mediated inﬂammation was relevant to diabetogenesis in
DRlyp/lyp rats, treatment with hIL-1Ra should delay onset
for approximately the amount of time required to mount a
robust antibody response (	10–14 days). Treatment was
initiated by day 30 and continued through type 1 diabetes
onset. Treated rats survived 71  11 days, whereas con-
trols survived 61  6 days (P  0.007) (Fig. 4A). Signiﬁcant
differences in weight or growth rate were not observed
between treated and control rats (P  0.05). As expected,
the animals possessed antibody titer to hIL-1Ra (Fig. 4B).
Use of transcriptional signature to monitor effect of
IL-1R blockade. To determine whether hIL-1Ra treatment
of DRlyp/lyp rats would result in modulation of the serum
signature, additional rats were treated with hIL-1Ra or
saline for 10 days, beginning at day 30. Serum was col-
lected at day 40 and assayed to determine 1) whether an
inﬂammatory signature was present at this time prior to
insulitis (27), 2) whether day 40 and day 60 signatures
were similar, and 3) whether a day 40 signature was
modulated in hIL-1Ra–treated rats. Furthermore, after
only 10 days of treatment, the effect of hIL-1Ra treatment
would be less likely masked by the high concentrations of
neutralizing antibodies observed at onset (Fig. 4B, lower
panels).
Regulated probe sets between cultures possessing se-
rum of saline- or hIL-1Ra–treated DRlyp/lyp rats compared
with allogeneic BN serum were identiﬁed and subjected to
hierarchical clustering (Fig. 4C and D). In the PBS-treated
DRlyp/lyp versus BN allogeneic comparison, 1,526 probe
sets met these criteria, and among these, a signiﬁcant
percentage (638 of 1,526, 41.8%; P  10
6 

2 test) were
also regulated by day 60 DRlyp/lyp sera. Ontological
analysis again identiﬁed biological processes related to an-
tigen presentation, inﬂammation, leukocyte migration, and
activation of the NFB cascade (Table 1 and supplement
2). Selected genes related to these pathways are shown
(Fig. 4E, supplement A). Compared with BN sera, sera of
day 40 DRlyp/lyp rats treated with hIL-1Ra regulated only
ﬁve probe sets. The two probe sets of the intersection
exhibited directionally concordant inductions by either
saline-treated DRlyp/lyp or IL-1Ra–treated DRlyp/lyp sera
relative to allogeneic BN sera. As reﬂected by the fold
changes illustrated in Fig. 4D, treatment reduced induction
of the proinﬂammatory signature observed in PBS-treated
rats. Overall, these results show that like human type 1
diabetes (13), a serum-induced signature with identity to
that observed at onset is detected prior to onset in the
DRlyp/lyp rat. Moreover, this signature is modulated by
treating rats with hIL-1Ra, suggesting that this approach
may prove useful in monitoring the effect of therapeutic
interventions in human type 1 diabetes.
DISCUSSION
Previously, we deﬁned a transcriptional signature induced
by sera of human type 1 diabetic patients (13). Here,
parallel studies were conducted that deﬁned unique signa-
tures for diabetes-inducible DR/ and spontaneously
diabetic DRlyp/lyp rats. Like human type 1 diabetes, the
signature associated with disease progression in DRlyp/
lyp rats includes many genes regulated by IL-1 and differ-
ential regulation of NFB signaling is a key feature
distinguishing the signatures induced by sera of the DRlyp/
lyp and DR/ substrains.
Identity is observed between signatures induced by day
60 serum of DRlyp/lyp and DR/ rats, in particular the
912 probe sets of the DRlyp/lyp:DR/ intersection.
Identity is also evident in 1,992 probe sets regulated to
threshold levels by DR/ serum. These probe sets,
annotated as immunoregulatory, are regulated by DRlyp/
lyp serum to a lesser degree that does not meet threshold
values. This suggests the presence of endogenous, albeit
insufﬁcient, immunoregulatory activity in DRlyp/lyp rats
and may explain why relatively few (10
6) adoptively trans-
ferred DR/ TREG cells prevent type 1 diabetes in
FDR <0.10). PBMCs of six BN rats each were cultured with a serum pool generated from six hIL-1Ra–treated DRlyp/lyp rats or a serum pool
generated from six PBS-treated DRlyp/lyp rats (n  12 cultures). For PBMCs of each donor BN rat (n  6), a culture possessing autologous sera
was prepared. Fifteen cultures possessing allogeneic BN serum were prepared. Global gene expression was measured in each culture and all data
were normalized with that of the autologous induction to account for gene expression induced by placing the PBMCs into culture. D: Regulated
probes were identiﬁed between the PBS-treated DRlyp/lyp vs. BN allogeneic and hIL-1Ra–treated DRlyp/lyp vs. BN allogeneic inductions,
replicates were averaged, and the relatedness of the three conditions were examined by hierarchical clustering. E: Well-annotated, regulated
probe sets regulated by sera of PBS-treated DRlyp/lyp rats vs. the BN allogeneic induction. *Orthologues regulated by human type 1 diabetes sera
(13). The scale represents the fold of change between the serum tested relative to autologous serum (fourfold to fourfold). (A high-quality
digital representation of this ﬁgure is available in the online issue.)
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probe sets regulated by DRlyp/lyp sera, the DRlyp/lyp and
DR/ signatures are distinct, with the DRlyp/lyp signa-
ture possessing an IL-1–driven component that is down-
regulated by adding IL-1Ra to the culture.
Among human type 1 diabetic patients, a signiﬁcant
percentage will develop autoimmune thyroid disease (28).
Likewise, lymphopenic BB rats develop autoimmune thy-
roiditis. Since the method measures the sum of the inﬂam-
matory factors present in serum, we cannot exclude that
thyroid autoimmunity has not contributed to the signature
deﬁned for DRlyp/lyp rats. In terms of other models, we
have examined serum signatures associated with type 1
diabetes in LEW.1WR1 rats (29) and ﬁnd the inﬂammatory
states distinct but sharing partial identity (supplement C)
(30).
Despite the challenges of directly measuring peripheral
cytokine levels in human type 1 diabetes, studies have
established that a complex cytokine milieu exists. This
includes elevated IL-1 family members in patient cohorts
before and after disease onset (31–35). Here, ELISA anal-
ysis was unable to detect differences in IL-1/-
 levels
between DRlyp/lyp,D R / or BN rat sera. This may be
related to assay sensitivity, the limited number of rats
analyzed, or presence of soluble IL-1 receptors, which
impairs detection of free bioactive IL-1 and highlights the
need for new, more sensitive biomarkers. Given that the
amount of IL-1 (1 ng/ml) spiked into the autologous BN
cultures exceeded the sensitivity of the multiplex cytokine
analysis for IL-1
 (27 pg/ml) and IL-1 (27 pg/ml), the
signatures induced by DRlyp/lyp and DR/ sera (in
particular genes of the intersection) are not likely an effect
of IL-1 concentrations exclusively but involve the contri-
bution of other inﬂammatory mediators. Binding of IL-1
and LPS to their respective receptors initiate transcrip-
tional programs similar to those observed. We found LPS
levels in BB rats nearly twice that of BN rats, consistent
with reported intestinal hyperpermeability in BB rats (36),
which may lead to the translocation of bacteria and/or
endotoxin and a heightened systemic inﬂammatory state.
IL-13 was elevated in DRlyp/lyp compared with DR/
and BN serum. This is consistent with elevated IgE levels
and eosinophilia prior to onset in DRlyp/lyp rats (37), as
IL-13 induces immunoglobulin isotype switching to IgE in
B-cells and regulates eosinophilic inﬂammation.
In vitro, human and rodent pancreatic -cells are highly
susceptible to the actions of IL-1 (38), and IL-1Ra can
protect -cells from the downstream consequences of IL-1
exposure (39). While IL-1 transcript and protein are de-
tected within immune inﬁltrated pancreatic islets of BB
rats and NOD mice (40–42), in vivo modulation of either
ligand or receptor in these models has yielded mixed
results. Administration of high doses of IL-1 to diabetes-
prone BB rats induced higher blood glucose concentra-
tions before and at type 1 diabetes onset and accelerated
onset (43). In contrast, administration of IL-1 to the NOD
mouse delayed onset and reduced incidence (44,45). IL-1R
deﬁciency in the NOD mouse slowed progression to type 1
diabetes but did not prevent it (46), and treatment of NOD
mice with IL-1Ra inhibited recurrence of type 1 diabetes
after islet transplantation (47). IL-1 has been shown to
exacerbate autoimmunity by promoting expansion of ef-
fector T-cells and attenuating TREG cell function (48),
raising the possibility of IL-1–mediated impaired regula-
tory function of TREG cells in DRlyp/lyp relative to DR/
rats. Treatment of DRlyp/lyp rats with hIL-1Ra delayed
onset for the time required to mount a neutralizing hu-
moral immune response. These results are consistent with
a previous study in which hIL-1Ra delayed BB rat type 1
diabetes onset but did not affect growth or modify lym-
phocyte counts (16). As reported here, anti–hIL-1Ra anti-
bodies developed, to which short-term protection (2–3
weeks) was attributed. Importantly, with delayed onset we
observe modulation of the serum-induced transcriptional
proﬁle in hIL-1Ra–treated rats.
These ﬁndings support that this bioassay may not only
have utility as an early mechanistically informative inﬂam-
matory biomarker of type 1 diabetes but may prove useful
in monitoring changes in inﬂammatory state during thera-
peutic interventions, including those targeting IL-1 (49).
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